| Not Yet Recruiting | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMI NCT07220187 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Sub NCT06863402 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation NCT06735664 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome NCT06676033 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Recruiting | CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Gro NCT06926205 | GELLC (Grupo Español de Leucemia Linfocítica Crónica) | Phase 2 |
| Withdrawn | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From NCT06247540 | Northwestern University | Phase 2 |
| Recruiting | Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With NCT06186648 | French Innovative Leukemia Organisation | Phase 2 |
| Not Yet Recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502 | Ruijin Hospital | — |
| Recruiting | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation NCT05672173 | City of Hope Medical Center | Phase 2 |
| Recruiting | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic NCT05388006 | Mayo Clinic | Phase 2 |
| Withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformat NCT04781855 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Terminated | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndro NCT04978779 | Vincerx Pharma, Inc. | Phase 1 |
| Active Not Recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation NCT04679012 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Completed | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma NCT03892044 | David Bond, MD | Phase 1 |
| Recruiting | A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome NCT03899337 | University of Birmingham | Phase 2 |
| Completed | BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation NCT03931642 | French Innovative Leukemia Organisation | Phase 2 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Dr NCT03321643 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS NCT03534323 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Unknown | Genomic and Proteomic Study of Richter Syndrome (CGPSR) NCT03619512 | Central Hospital, Nancy, France | — |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Terminated | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies NCT03205046 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Terminated | Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patient NCT03145480 | Northwell Health | Phase 2 |
| Active Not Recruiting | A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's NCT03054896 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymph NCT02846623 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia NCT02530515 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell NCT02576990 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL NCT02535286 | TG Therapeutics, Inc. | Phase 1 |
| Completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphoc NCT02420912 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymp NCT02285244 | James Blachly | Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Terminated | Allogeneic Stem Cell Transplant for CLL NCT01629511 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |